

**Amendments to the Claims under 37 C.F.R. § 1.121**

Claim 1 (currently amended):       A trimeric polypeptide comprising three monomers, each of said monomers comprising a specific binding member capable of binding a trimeric cytokine, and each of said monomers comprising a trimerising domain, the trimerising domain is derived from tetranectin.

Claims 2-17 (cancelled).

Claim 18 (currently amended):       The A trimeric polypeptide according to claim ~~17~~ 1, wherein the trimerising domain derived from tetranectin comprises a sequence having at least 68% amino acid sequence identity with the sequence of SEQ ID NO:81.

Claim 19 (currently amended):       The A-trimeric polypeptide according to claim 18, wherein the amino acid sequence identity is at least 92%.

Claim 20 (currently amended):       The A-trimeric polypeptide according to claim ~~17~~ 1, wherein the trimerising domain derived from tetranectin comprises the amino acid sequence SEQ ID NO:81.

Claim 21 (currently amended):       The A-trimeric polypeptide according to claim ~~17~~ 1, wherein the monomer is selected from the group consisting of TN-2-B (SEQ ID NO:106), TN-2-C (SEQ ID NO:108), or TN-2-D (SEQ ID NO:107), and AD1D4-GSS-HO (SEQ ID NO:109).

Claim 22 (currently amended):       The A-trimeric polypeptide according to claim 1, further comprising a linker between the specific binding member and the trimerising domain.

Claim 23 (previously presented):    A pharmaceutical composition comprising the trimeric polypeptide according to claim 1.

Claims 24-29 (cancelled).

Claim 30 (currently amended):      A method of preparing a pharmaceutical composition[[,]] comprising combining the trimeric polypeptide according to claim 1 with a pharmaceutically acceptable carrier.

Claims 31-34 (cancelled).

Claim 35: (currently amended):      The A-trimeric polypeptide according to claim 20, wherein the cysteine residue number 50 is mutagenized to serine, threonine, methionine, or any other amino acid residue.